Top Picks: Accredited Activities

Breaking New Ground in AML: Practical Applications of Emerging Treatment Options

Guillermo Garcia-Manero, MD; Jeffrey E. Lancet, MD; Elli Papaemmanuil, PhD; Richard Stone, MD

EHA 2017 Congress Highlights in Acute Myeloid Leukemia

Ehab Atallah, MD; Jorge E. Cortes, MD; Naval Daver, MD; Keith W. Pratz, MD; Eytan M. Stein, MD; Richard M. Stone, MD

  • Clinical Trials: CPX-351 and Vosaroxin: Developments in Chemotherapy for AML - J. Cortes, MD, F. Ravandi, MD - Posted 09/29
    text
  • VIDEO FAQ: What are the contributing factors to poor outcomes in older patients with AML? - A. Nazha, MD (1:45) - Posted 09/26
    video
  • VIDEO: Tailoring Therapy to Older Patients with Acute Myeloid Leukemia - A. Nazha, MD (30:46) - Posted 09/14
    CE video
  • PODCAST: Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study - E. Stein, MD (8:25) - Posted 08/21
    podcast
  • PODCAST: CPX versus 7 and 3 conventional chemotherapy in older adults with AML - S. Goldberg, MD (3:16) - Posted 08/07
    podcast
  • Additional activities...

Supporters

MediCom Worldwide, Inc. would like to recognize and thank the following companies for their educational support of Managing AML.com

  • Agios Pharmaceuticals, Inc.
  • Celgene Corporation
  • Helsinn
  • Incyte Corporation
  • Jazz Pharmaceuticals, Inc.
  • Novartis Pharmaceuticals

MediCom Oncology Links

Please visit these other members of the MediCom Oncology family of sites.

Managing MDS Managing Myeloma The Practical Oncologist
Managing Hodgkin Lymphoma Partners in Pancreatic Cancer Emerging Solutions in Pain